Form 4: Anteris Director Gregory Moss Acquires 17,580 Shares

Director Gregory S. Moss converted 17,580 restricted stock units into common stock following the first vesting installment of a 2025 equity grant.

Summary

• Gregory S. Moss, a Director at Anteris Technologies Global Corp., acquired 17,580 shares of common stock on June 7, 2026.
• The acquisition resulted from the vesting of the first of three installments of restricted stock units (RSUs) granted on December 3, 2025.
• Each RSU converted into one share of common stock at a conversion price of $0.00.
• Following the transaction, the reporting person directly owns 17,580 shares of common stock.
• The reporting person continues to hold 35,162 unvested RSUs scheduled to vest in 2027 and 2028.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event as it confirms director alignment with shareholders through direct stock ownership without any immediate selling pressure.

Positives

• Director maintains a direct equity stake in the company, aligning interests with shareholders.
• The vesting confirms the director's continued service and commitment to the board.
• The transaction was a planned conversion of derivative securities rather than a market sale.

Negatives

• The issuance of new shares upon vesting results in a minor dilutive effect on existing shareholders.

Risks

• Future dilution will occur as the remaining 35,162 RSUs vest over the next two years.
• The value of the compensation is tied to stock price performance, which may fluctuate based on clinical or regulatory milestones.

Future Outlook

The reporting person is scheduled to receive two additional equal installments of common stock in June 2027 and June 2028, provided they remain in service with the company.

Management Comments

• The restricted stock units generally vest in approximately equal installments on June 7, 2026, June 7, 2027, and June 7, 2028, subject to continued service.

Industry Context

StockSavvy.ai notes that equity-based compensation for directors is a standard practice in the medical technology industry to ensure board members are incentivized to drive long-term shareholder value, similar to structures seen at larger peers like Edwards Lifesciences.

Comparison to Industry Standards

• The three-year vesting schedule is consistent with standard corporate governance practices for non-employee director compensation in U.S. listed companies.
• The use of RSUs rather than options is increasingly common among growth-stage med-tech firms to reduce extreme volatility in executive compensation.

Related Party Transactions

• The issuance of shares to a Director under an equity incentive plan is considered a related party transaction under standard accounting definitions.

Stakeholder Impact

• Shareholders may experience minor dilution as RSUs are converted into outstanding common shares.
• Investors receive confirmation of board stability and continued participation by key directors.

Next Steps

• Monitor for the next vesting event scheduled for June 7, 2027.
• Watch for any subsequent Form 4 filings that might indicate the director is selling these newly acquired shares.

Key Dates

Recommendation

This is a routine regulatory filing regarding director compensation and does not provide new material information regarding the company's operations or financial health that would warrant a change in investment thesis.

Keywords

Anteris Technologies, AVR, Insider Trading, Form 4, Restricted Stock Units, Gregory Moss, Executive Compensation, Director Holdings